Intrauterine device use and risk of ovarian cancer: Results from the New England Case‐Control study and Nurses' Health Studies
Abstract
Results of studies assessing intrauterine device (IUD) use and ovarian cancer risk are inconsistent. We examined the association between IUD use, including duration, type and timing of use, and ovarian cancer risk using three population‐based studies. Data from the New England Case‐Control Study (NEC) and two prospective cohort studies, the Nurses' Health Studies (NHS/NHSII), were included in the analysis. Information on IUD use was collected by in‐person interview in NEC and by biennial questionnaire in NHS/NHSII. We used unconditional logistic regression to calculate odds ratios (OR) and 95% confidence intervals (CI) in NEC and Cox regression to calculate hazard ratios (HR) and 95% CI in NHS/NHSII. We used meta‐analysis to combine the NEC and the pooled NHS/NHSII results. Overall, IUD use was not associated with epithelial ovarian cancer risk (OR = 0.96, 95% CI: 0.81‐1.14 in NEC; HR = 0.89, 95% CI: 0.69‐1.15 in NHS/NHSII; combined RR = 0.94, 95% CI: 0.81‐1.08). Among IUD users, older age at first use was associated with increased ovarian cancer risk (P‐trend = .03). We did not observe significant associations by IUD type or duration of use. In conclusion, IUD use was not associated with ovarian cancer risk in our study.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 17, 2021
- Source ID
- 10.1002/ijc.33531
Entities
People
- Allison F. Vitonis
- Ana Babic
- Daniel W. Cramer
- Jiaxi Yang
- Kathryn L. Terry
- Linda Titus
- Mary K Townsend
- Naoko Sasamoto
- Shelley S. Tworoger
Organizations
- Dana–Farber Cancer Institute
- H. Lee Moffitt Cancer Center & Research Institute
- Harvard Medical School
- Harvard University
- United States Department of Defense
- University of Southern Maine